ECSP23030307A - Variantes de anticuerpos felinos - Google Patents

Variantes de anticuerpos felinos

Info

Publication number
ECSP23030307A
ECSP23030307A ECSENADI202330307A ECDI202330307A ECSP23030307A EC SP23030307 A ECSP23030307 A EC SP23030307A EC SENADI202330307 A ECSENADI202330307 A EC SENADI202330307A EC DI202330307 A ECDI202330307 A EC DI202330307A EC SP23030307 A ECSP23030307 A EC SP23030307A
Authority
EC
Ecuador
Prior art keywords
variants
feline
feline antibodies
antibodies
relates
Prior art date
Application number
ECSENADI202330307A
Other languages
English (en)
Inventor
Lisa Marie Bergeron
Henry Luis Campos
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of ECSP23030307A publication Critical patent/ECSP23030307A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere generalmente a variantes de anticuerpos felinos y usos de estos. Específicamente, la invención se refiere a mutaciones en la región constante del anticuerpo felino para mejorar su semivida y otras características.
ECSENADI202330307A 2020-09-29 2023-04-25 Variantes de anticuerpos felinos ECSP23030307A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063084693P 2020-09-29 2020-09-29

Publications (1)

Publication Number Publication Date
ECSP23030307A true ECSP23030307A (es) 2023-07-31

Family

ID=78599139

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202330307A ECSP23030307A (es) 2020-09-29 2023-04-25 Variantes de anticuerpos felinos

Country Status (16)

Country Link
US (1) US20230382986A1 (es)
EP (1) EP4221744A1 (es)
JP (1) JP2023542737A (es)
KR (1) KR20230091914A (es)
CN (1) CN116457369A (es)
AR (1) AR123645A1 (es)
AU (1) AU2021352395A1 (es)
CA (1) CA3195049A1 (es)
CL (1) CL2023000914A1 (es)
CO (1) CO2023004107A2 (es)
EC (1) ECSP23030307A (es)
IL (1) IL301414A (es)
MX (1) MX2023003694A (es)
PE (1) PE20240110A1 (es)
TW (2) TWI814094B (es)
WO (1) WO2022072446A1 (es)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
BRPI0515230A (pt) 2004-08-19 2008-07-15 Genentech Inc polipeptìdeos, anticorpos e ácidos nucléicos isolados, composições, vetor de expressão, células hospedeiras isoladas, método para a produção de um anticorpo, artigos manufaturados, métodos de tratamento e para o alìvio de disfunções, métodos de produção e de seleção de um polipeptìdeo, anticorpo de ligação cd20 humanizado, anticorpo anti-her2 isolado e usos de um anticorpo
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
EP2845865A1 (en) 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
EP3575317A1 (en) * 2007-12-26 2019-12-04 Xencor, Inc. Fc variants with altered binding to fcrn
ES2910305T3 (es) 2010-08-19 2022-05-12 Zoetis Belgium S A Anticuerpos anti-NGF y su uso
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
US20190248881A1 (en) * 2017-12-04 2019-08-15 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
AU2019360271A1 (en) * 2018-10-18 2021-04-29 Elanco Us Inc. Fc variants with altered binding to neonatal Fc receptor (FcRn) for veterinary use
CN113227134A (zh) * 2018-12-05 2021-08-06 株式会社梅花治疗 抗体的Fc区变体
WO2021212084A1 (en) * 2020-04-17 2021-10-21 Zoetis Services Llc Feline antibody variants

Also Published As

Publication number Publication date
WO2022072446A1 (en) 2022-04-07
EP4221744A1 (en) 2023-08-09
US20230382986A1 (en) 2023-11-30
TW202413413A (zh) 2024-04-01
MX2023003694A (es) 2023-04-21
JP2023542737A (ja) 2023-10-11
TW202222830A (zh) 2022-06-16
KR20230091914A (ko) 2023-06-23
CN116457369A (zh) 2023-07-18
TWI814094B (zh) 2023-09-01
CO2023004107A2 (es) 2023-04-27
CL2023000914A1 (es) 2023-10-20
PE20240110A1 (es) 2024-01-22
CA3195049A1 (en) 2022-04-07
AR123645A1 (es) 2022-12-28
IL301414A (en) 2023-05-01
AU2021352395A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
CL2023003377A1 (es) Variantes de anticuerpos caninos
CL2023003376A1 (es) Variantes de anticuerpos felinos
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
CL2023000896A1 (es) Receptores quiméricos de dll3 y métodos para su uso
EA202092847A1 (ru) Антитела к cd3 и их применение
BR112018067458A2 (pt) anticorpos para tigit
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
CO2023007146A2 (es) Variantes de anticuerpos bovinos
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
ECSP23030271A (es) Variantes de anticuerpos caninos
EA202092202A1 (ru) Конструкции антител к ror
CL2023001781A1 (es) Mutaciones en regiones constantes de anticuerpos felinos
EA201992776A1 (ru) Белки на основе антитела с привитым цитокином и способы их применения при иммунных нарушениях
EA202092849A1 (ru) Моноспецифические и мультиспецифические антитела к tmeff2 и их применение
CO2023009994A2 (es) Mutaciones en regiones constantes de anticuerpos caninos
EA201891594A1 (ru) Антитела к il-17c
ECSP23030307A (es) Variantes de anticuerpos felinos
PE20230259A1 (es) Anticuerpos anti-tgf-beta con selectividad de isoforma y metodos de uso
TR202104726A2 (tr) Köfte form maki̇nasinda yeni̇li̇k
EA202091973A1 (ru) Конструкции слитых белков, содержащие анти-muc1 антитело и il-15
MX2023010648A (es) Novedosas combinaciones de anticuerpos y usos de estas.
EA202192113A1 (ru) Антитела, распознающие тау
EA201991614A1 (ru) СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ